Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
– Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success...
-
- The Ministry of Health has set a 180-working-day review period for the MAA - - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C.,...
-
- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitment received for a minimum of $1.475 million for a...
-
- Mr. McElheney brings more than 15 of years’ experience in corporate development and alliance management at biopharma companies. - - He will work with the Company’s leadership team to expand...
-
DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at...
-
DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at...
-
Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results...
-
- Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval - - Preparation is underway for expansion of Symvess into...
-
DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at...
-
- Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society - - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb...